CANCER GENE MUTATION DETECTION
CBI offers molecular diagnostic tests for detecting mutations and measuring gene expression in FFPE cancer tissue. Some kits have been tested for detection of mutations in cfDNA isolated from plasma.
The assays are based on a real-time PCR technology and have outstanding sensitivity (1%) and accuracy (99%). The list of genes includes: EGFR, KRAS, BRAF, PIK3CA, EML4-ALK, ROS1, ALK/ROS1, JAK2, KIT, BCR-ABL, PIK3CA, P53 and the RET oncogene. Quantitative gene expression assays for excision repair (ERCC1), thymidine phosphorylase (TYMP), stathmin (STMN1), ribonucleotide reductase (RRM1) and other genes provide valuable information to help predict chemotherapy responses.
The assays are easy to perform, provide results in 90 minutes, and have been validated on several PCR instruments that are commonly used in diagnostic laboratories.